These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: correlation with tumor stage and histology. Catalona WJ; Chretien PB Cancer; 1973 Feb; 31(2):353-6. PubMed ID: 4687881 [No Abstract] [Full Text] [Related]
6. Quantitative dinitrochlorobenzene contact sensitivity in preoperative and cured cancer patients. Chretien PB; Twomey PL; Trahan EE; Catalona WJ Natl Cancer Inst Monogr; 1973 Dec; 39():263-6. PubMed ID: 4787068 [No Abstract] [Full Text] [Related]
7. Inhibition of phytohemagglutinin-induced in vitro lymphocyte transformation by serum from patients with carcinoma. Sample WF; Gertner HR; Chretien PB J Natl Cancer Inst; 1971 Jun; 46(6):1291-7. PubMed ID: 5088049 [No Abstract] [Full Text] [Related]
8. Proceedings: Evaluation of immune status in tumor patients. Vetto RM; Burger DR; Lilley DP Arch Surg; 1974 Apr; 108(4):558-60. PubMed ID: 4131415 [No Abstract] [Full Text] [Related]
9. Increase of lymphocyte-mediated tumor-cell destruction by certain patient sera. Hellström I; Hellström KE; Warner GA Int J Cancer; 1973 Sep; 12(2):348-53. PubMed ID: 4792348 [No Abstract] [Full Text] [Related]
10. Cellular and humoral immunity to different types of human neoplasms. Hellström I; Hellström KE; Pierce GE; Yang JP Nature; 1968 Dec; 220(5174):1352-4. PubMed ID: 4302696 [No Abstract] [Full Text] [Related]
11. Evidence for immune reactivity against neoplasms. McKhann CF; Jagarlamoody SM Transplant Rev; 1971; 7():55-77. PubMed ID: 4112673 [No Abstract] [Full Text] [Related]
12. Immunologic impairment in bronchogenic carcinoma: a study of lymphocyte response to phytohemagglutinin. Han T; Takita H Cancer; 1972 Sep; 30(3):616-20. PubMed ID: 4342406 [No Abstract] [Full Text] [Related]
13. [Clinical significance of the subsets of lymphocyte in the peripheral blood of the head and neck cancer patients]. Okamoto M; Takahashi H; Yao K; Fujino A; Ishii T; Harada K; Yagi A; Yoshio S; Yagi K; Furusawa S Nihon Jibiinkoka Gakkai Kaiho; 1985 Apr; 88(4):443-8. PubMed ID: 4032110 [No Abstract] [Full Text] [Related]
14. Nonspecific lymphocyte cytotoxicity in patients with malignant melanoma, renal cell carcinoma, and sarcomas, and in nontumor patients. Bukowski RM; Barna B; Deodhar SD; Hewlett JS Cancer; 1976 Nov; 38(5):1962-7. PubMed ID: 991109 [TBL] [Abstract][Full Text] [Related]
15. A correlative analysis of in vitro parameters of cellular immunity in patients with squamous cell carcinoma of the head and neck. Deegan MJ; Coulthard SW; Quaiman SJ; Schork MA Cancer Res; 1977 Dec; 37(12):4475-81. PubMed ID: 144562 [No Abstract] [Full Text] [Related]
16. Immune reactivity in head and neck squamous carcinoma and relevance to the design of immunotherapy trials. Browder JP; Chretien PB Semin Oncol; 1977 Dec; 4(4):431-9. PubMed ID: 339354 [No Abstract] [Full Text] [Related]
18. DNCB sensitivity in cancer patients. A review based on sequential testing in 430 patients. Bolton PM Clin Oncol; 1975 Mar; 1(1):59-69. PubMed ID: 1106933 [No Abstract] [Full Text] [Related]
19. Immunologic abnormalities in head and neck cancer. Eilber FR; Morton DL; Ketcham AS Am J Surg; 1974 Oct; 128(4):534-8. PubMed ID: 4422512 [No Abstract] [Full Text] [Related]
20. Immunological status of patients in carcinoma head and neck. Vasenwala SM; Aziz M; Rattan A; Ahmad KN Indian J Cancer; 1989 Sep; 26(3):137-44. PubMed ID: 2630426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]